A1, an innovative fluorinated CXCR4 inhibitor, redefines the therapeutic landscape in colorectal cancer

A1, an innovative fluorinated CXCR4 inhibitor, redefines the therapeutic landscape in colorectal cancer

Abstract Background Colorectal cancer (CRC) is a globally prevalent malignancy, primarily affecting the colon and rectum, characterized by uncontrolled cellular changes in the intestinal wall lining. Recent evidence underlines the significant role of the CXCL12/CXCR4 axis in the development of CRC,...

Full description

Saved in:
Bibliographic Details
Main Authors: Hossein Khorramdelazad, Kowsar Bagherzadeh, Ali Rahimi, Ali Darehkordi, Alireza Najafi, Milad Karimi, Majid Khoshmirsafa, Gholamhossein Hassanshahi, Elaheh Safari, Reza Falak
Format: Article
Language:English
Published: BMC 2025-01-01
Series:Cancer Cell International
Subjects:
AMD3100
Colorectal cancer
CXCR4 inhibitor
CXCL12
Fluorine
Online Access:https://doi.org/10.1186/s12935-024-03584-y
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12935-024-03584-y

Similar Items